Clinical trials: Anxiety, Generalized
Anxiety Disorder
A 10-Week Efficacy and Safety Study of Gabitril in the Treatment of Adults With Generalized Anxiety Disorder
The purpose of this study is to evaluate the safety and efficacy of an investigational anti-anxiety medication relative to placebo in patients with generalized anxiety disorder (GAD).
- Trial name
- NCT00236015
- Testing
- Gabitril
- Where
- 54 sites in United States, Canada
- Volunteers
- 880 people
- Sponsor
- Cephalon
Anxiety Disorders
Duloxetine Compared With Placebo in Patients With Generalized Anxiety Disorder
This is a clinical trial assessing duloxetine compared with placebo in patients who have generalized anxiety disorder.
- Trial name
- NCT00122824
- Testing
- duloxetine hydrochloride
- Where
- 7 sites in United States, Finland and 5 more
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Anxiety Disorders
A Comparison of Duloxetine Hydrochloride, Marketed Comparator, and Placebo in the Treatment of Generalized Anxiety Disorder
This study will examine duloxetine compared with placebo and an active comparator in the treatment of generalized anxiety disorder.
- Trial name
- NCT00122850
- Testing
- Duloxetine, venlafaxine
- Where
- 19 sites in United States
- Volunteers
- 480 people
- Sponsor
- Eli Lilly and Company
Anxiety Disorder
Experimental Medication For the Treatment of Generalized Anxiety Disorder
The purpose of this study is to determine whether an experimental anti-anxiety medication is effective in the treatment of Generalized Anxiety Disorder.
- Trial name
- NCT00097708
- Testing
- experimental anti-anxiety drug
- Where
- 50 sites in United States
- Volunteers
- 511 people
- Sponsor
- Jazz Pharmaceuticals
Generalized Anxiety Disorder
Phase Ⅲ Clinical Trial of Buagafuran Capsules in the Treatment of GAD
A placebo-controlled superiority design was used to evaluate the efficacy of 60-120 mg/ day of Buagafuran capsules in the treatment of GAD.
- Trial name
- BGFN-2022-01 (NCT06243614)
- Testing
- Buagafuran capsules, 15mg/ capsule, Buspirone tablets, 5mg/ tablet, Buagafuran capsules mimic, 0mg/ capsule
- Where
- China
- Volunteers
- 410 people
- Sponsor
- Beijing Union Pharmaceutical Factory Ltd
Generalized Anxiety Disorder
A Study to Evaluate Efficacy and Safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets in Generalized Anxiety Disorder.
The study aims to evaluate the efficacy and safety of Toludesvenlafaxine Hydrochloride Sustained-release Tablets compared to placebo in adults participants with generalized anxiety disorder over a period of 8 weeks.
- Trial name
- NCT05970510
- Testing
- Toludesvenlafaxine Hydrochloride Sustained-release Tablet 80mg, Toludesvenlafaxine Hydrochloride Sustained-release Tablet 160mg
- Where
- China
- Volunteers
- 555 people
- Sponsor
- Luye Pharma Group Ltd.
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Elderly Patients With Generalized Anxiety Disorder
The primary objective of this study is to demonstrate the efficacy of SR58611A 350 mg twice a day compared to placebo in elderly patients with Generalized Anxiety Disorder (GAD), as assessed by the 14-item Hamilton Anxiety rating…
- Trial name
- GEMINI (NCT00535340)
- Testing
- SR58611A
- Where
- 5 sites in Austria, Croatia and 3 more
- Volunteers
- 55 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
RE104 Safety and Efficacy Study in Generalized Anxiety Disorder
The purpose of this study is to determine if treatment with a single and/or repeat dose of RE104 for Injection reduces anxiety symptoms in participants with Generalized Anxiety Disorder (GAD) as compared to placebo.
- Trial name
- NCT07489651
- Testing
- RE104 for Injection
- Where
- 28 sites in United States
- Volunteers
- 160 people
- Sponsor
- Reunion Neuroscience Inc
Anxiety Disorders,Generalized Anxiety Disorder
A Study of Escitalopram in the Treatment of Children and Adolescents With Generalized Anxiety Disorder
This is a study in minors (7 to 17 years old) diagnosed with generalized anxiety disorder (GAD) and evaluated using standard questionnaires as having at least moderate severity of GAD.
- Trial name
- NCT03924323
- Testing
- Escitalopram
- Where
- 39 sites in United States
- Volunteers
- 273 people
- Sponsor
- AbbVie
PTSD, Generalized Anxiety Disorder
Feasibility and ML Training Investigation of the Senseye DT for Diagnosis of Adults with PTSD
The aim of this study is to obtain data on the feasibility of the Senseye Diagnostic Tool (DT) to assess the presence and severity of post-traumatic stress disorder (PTSD) symptoms.
- Conditions
- PTSD, Generalized Anxiety Disorder, Major Depressive Disorder
- Trial name
- NCT05717439
- Testing
- CAPS-5-R, Senseye DT
- Where
- 5 sites in United States
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Senseye, Inc.
Generalized Anxiety Disorder
A Trial of the Efficacy and Safety of a Fixed Dose of SEP-363856 in Adults With Generalized Anxiety Disorder
This is a global, phase 3, randomized, double-blind, parallel-group, 2-arm, placebo controlled, multicenter trial designed to compare the efficacy, safety and tolerability of a fixed dose of SEP-363856 (75 millligrams per day…
- Trial name
- NCT07767903
- Testing
- SEP-363856
- Where
- 11 sites in United States
- Volunteers
- 384 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Generalized Anxiety Disorder
Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder
The purpose of this study is to evaluate the efficacy, safety and tolerability of vilazodone relative to placebo in the treatment of generalized anxiety disorder (GAD)
- Trial name
- VLZ-MD-05 (NCT01629966)
- Testing
- Vilazodone
- Where
- 37 sites in United States
- Volunteers
- 680 people
- Sponsor
- Forest Laboratories
Generalized Anxiety Disorder
Empower Neuromodulation System - Pilot Study for Anxiety Treatment
This study evaluates the effects of peripheral nerve stimulation on anxiety levels in participants with Generalized Anxiety Disorder (GAD).
- Trial name
- NCT04901481
- Testing
- Empower Neuromodulation System
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Theranova, L.L.C.
All Diagnosed Health Conditions, ADD/ADHD
At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
We are the missing link in clinical trials, connecting patients and researchers seamlessly and conveniently using a mobile health platform to advance medical research.
- Conditions
- All Diagnosed Health Conditions, ADD/ADHD, Alopecia Areata, Ankylosing Spondylitis
- Trial name
- NCT01931644
- Where
- United States
- Volunteers
- 17,667 people, healthy volunteers welcome
- Sponsor
- Sanguine Biosciences
Anxiety Disorders
Study Of Remission In Patients Treated For Generalized Anxiety Disorder
The aim of the study is to assess the remission rates in patients treated for generalized anxiety disorder in primary and specialized care.
- Trial name
- NCT01788553
- Testing
- remission prevalence of generalized anxiety disorder
- Where
- Belgium
- Volunteers
- 750 people
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Anxiety Disorders
Clinical Study Assessing a New Scale to Measure Onset of Action in Generalized Anxiety Disorder
The study is to assess the performance characteristics of a new measure to assess onset of efficacy in a GAD patient population.
- Trial name
- NCT00715039
- Testing
- lorazepam, paroxetine
- Where
- 15 sites in United States
- Volunteers
- 169 people
- Sponsor
- Pfizer
Major Depressive Disorder (MDD, Anxiety Disorder, Generalized
Serotonin Variants & Gut Microbiota in Mental Health
This observational pilot study investigates whether a broad panel of genetic variants relevant to the serotonin pathway (including serotonergic system, methylation cycle, intestinal barrier integrity, and inflammatory response…
- Conditions
- Major Depressive Disorder (MDD, Anxiety Disorder, Generalized, Stress Disorders, Post-Traumatic, Panic Disorder
- Trial name
- NCT07634458
- Testing
- SNP Genotyping and Gut Metagenomics
- Volunteers
- 30 people
- Sponsor
- Neurobiologix
Anxiety Disorders
An Eight-Week Study to Evaluate the Efficacy and Safety of SR58611A in Patients With Generalized Anxiety Disorder
The purpose of the study is to evaluate the efficacy and safety of SR58611A in patients with Generalized Anxiety Disorder. The primary objective is to evaluate the efficacy of a 350 mg and 700 mg dose of SR58611A compared to…
- Trial name
- ELECTRA (NCT00332891)
- Testing
- SR58611A
- Where
- 5 sites in Bulgaria, Croatia and 3 more
- Volunteers
- 508 people
- Sponsor
- Sanofi
Generalized Anxiety Disorder
A Study of MK0777 Gel Extrusion Module (GEM) in the Treatment of Outpatients With Generalized Anxiety Disorder (0777-019)
The study will look at the effectiveness of MK0777 in patients with Generalized Anxiety Disorder.
- Trial name
- NCT00703833
- Testing
- MK0777
- Volunteers
- 51 people
- Sponsor
- Merck Sharp & Dohme LLC
Generalized Anxiety Disorder
A Clinical Study That Will Measure How Well SEP-363856 Works and How Safe it is in Adults With Generalized Anxiety Disorder
A clinical study that will meaure how well SEP-363856 works and how safe it is in adults with Generalized Anixety Disorder. This study will be accepting both male and female subjects between the ages of 18 years and 65 years old.
- Trial name
- NCT05729373
- Testing
- SEP-363856
- Where
- 83 sites in United States, Bulgaria and 6 more
- Volunteers
- 434 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.